In the development of vaccines for treatment against SARS-CoV-2, several categories have emerged and their benefits and concerns have become apparent. An ideal target, the Spike (S) protein, has emerged and become the focus of recombinant vaccines. The S protein is crucial for the infection process of SARS-CoV-2. Recombinant vaccines make use of this and focus on creating an immune response targeting the S protein. There are various subcategories of recombinant vaccines and all function in a fundamentally similar manner. Two other types of vaccines are live-attenuated and inactivated vaccines. They utilize weakened or inactivated coronavirus to create an immune response, unlike recombinant vaccines. Nucleic acid-based coronavirus vaccines are a subcategory of recombinant vaccines and include DNA- and RNA-based vaccines. Recombinant vaccines make full use of the presented target and efficiently provide superior treatment against SARS-CoV-2.
Research Paper by Eesha Lingala. Grade 9, Nashua, New Hampshire